You may have heard about Biktarvy, a medicine approved by the FDA in 2018 to treat people with HIV who have not been treated yet. It may also be used to replace another medicine for treating HIV in ...

Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching toward a 2033 patent cliff, the drugmaker at its HIV investor event laid out an ...

Investing.com -- Gilead Sciences Inc. (NASDAQ:GILD) stock rose 4.5% Monday after the company announced it had settled patent disputes with multiple generic drugmakers over its HIV treatment Biktarvy.

DUBLIN--(BUSINESS WIRE)--The "Biktarvy - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering. Biktarvy - Drug Insight, 2019 report provides comprehensive information of the ...

Results showed that after switching to Biktarvy, 100% of patients 6 to <12 years of age and 98% of patients 12 to <18 years of age remained virologically suppressed (HIV-1 RNA <50 copies/mL). Adverse ...

Gilead Sciences, Inc., GILD announced that it has entered into settlement agreements to resolve the patent litigations with a few generic manufacturers who were looking to market generic versions of ...

The Food and Drug Administration has given Gilead the green light for a new low-dose tablet dosage form of Biktarvy (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) for ...

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced findings from two randomized, double-blind, active-controlled Phase 3 studies (Study 1489 and Study 1490) ...

No new safety or tolerability concerns were observed with Biktarvy during pregnancy and postpartum. The Food and Drug Administration (FDA) has approved updated labeling for Biktarvy ® (bictegravir ...

AbbVie remained the top pharma TV ad spender with Humira in June, and Gilead Sciences continued its TV push for Biktarvy and Truvada. But one longtime list placeholder dropped out of sight: Pfizer’s ...